Business
Currency:USD
2024/Q3
Stock NameRevenueRatio
BRUKINSA®690.28M68.92%
Tislelizumab163.35M16.31%
XGEVA®63.45M6.33%
BLINCYTO®20.22M2.02%
KYPROLIS®17.97M1.79%
Other14.89M1.49%
POBEVCY®12.19M1.22%
REVLIMID®11.1M1.11%
Collaboration revenue8.15M0.81%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
U.S.1.13B45.89%
China1.1B44.82%
Rest of world202.01M8.22%
Europe26.6M1.08%
